Zinzino AB Class B ZZ_B
OMXSTO · Sweden · Consumer Non-Durables
SEK 130.90-2.10 (-1.58%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The revenue in August for Zinzino's sales markets increased by 16 % and amounted to SEK 280.9 (242.5) million. Faun Pharma's external sales amounted to SEK 1.3 (3.4) million. Overall, the Group increased revenues by 15 % to SEK 282.2 (245.9) million compared with the previous year.
Based on the authorization granted by the Annual General Meeting on June 2, 2026, the Board of Directors of the Company has resolved on following directed share issue by way of set-off:
The revenue in July for Zinzino's sales markets increased by 20% and amounted to SEK 313.4 (261.6) million. Faun Pharma's external sales amounted to SEK 2.5 (2.2) million. Overall, the Group increased revenues by 20% to SEK 315.9 (263.8) million compared with the previous year.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.